City University

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Mercoledì, Febbraio 14, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Domenica, Febbraio 11, 2024
Pomerantz, City University, Court, Person, FDA, News, Data management, Neurobiology of Aging, Complaint, District court, Ext, Initiative, Safety, Cassava, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, Action Replay, Pharmaceutical industry

NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brooge, and Cassava and Encourages Investors to Contact the Firm

Retrieved on: 
Sabato, Febbraio 10, 2024
BIA, Fraud, Biomarker, Initiative, City University, P.C, Cassava Sciences, News, Science, FDA, Cassava, Data management, Defendant, Safety, Security (finance), Scientific misconduct, Alzheimer's disease, Cognition, Patient, Journal, Complaint, Neurobiology of Aging, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • For more information on the Brooge class action go to: https://bespc.com/cases/BROG
    Cassava is a clinical-stage biotechnology company.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • For more information on the Cassava class action go to: https://bespc.com/cases/SAVA

CASSAVA DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options

Retrieved on: 
Giovedì, Febbraio 8, 2024
Biomarker, Initiative, City University, News, Science, FDA, Cassava Sciences, Advertising, Woman, Data management, Safety, Scientific misconduct, Alzheimer's disease, Cognition, Patient, Journal, LLP, Neurobiology of Aging, Court, Pharmaceutical industry

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) --  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Celebrating Excellence in Anatomy: AAA Awards Distinguished Members

Retrieved on: 
Giovedì, Febbraio 8, 2024
Pennsylvania State University, Harvard Medical School, California University, Cell biology, The Anatomical Record, Developmental Dynamics, Stanford University, North Carolina State University, Boston Children's Hospital, Public health, School, Cell, Conference, Associate, Medical education, Mentorship, McGill University, Human body, Hospital, Biomedical sciences, Pediatrics, Anatomical Sciences Education, Forensic anthropology, Anschutz Medical Campus, Dental school, Student, University, AAA, Genetics, Outline of health sciences, Research, Physiology, City University, Chemical engineering, Arkansas College, Division, Orthopedic surgery, UCSF, Dentistry

ROCKVILLE, Md., Feb. 8, 2024 /PRNewswire/ -- The American Association for Anatomy (AAA) is honored to announce its 2024 awards recipients. Eighteen of the association's 2,455 members have been selected because they advanced AAA's values: community, respect, inclusion, integrity, and discovery. 

Key Points: 
  • ROCKVILLE, Md., Feb. 8, 2024 /PRNewswire/ -- The American Association for Anatomy (AAA) is honored to announce its 2024 awards recipients.
  • Eighteen of the association's 2,455 members have been selected because they advanced AAA's values: community, respect, inclusion, integrity, and discovery.
  • The AAA awards program provides over $650,000 in awards, research grants, and scholarships annually.
  • "Being recognized by my AAA idols, mentors, and peers is a cherished honor, reaffirming my commitment to fostering curiosity, deep understanding, and innovation in anatomy education."

Cassava ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Martedì, Febbraio 6, 2024
Initiative, Science, Data management, Telephone, City University, Cassava Sciences, News, Biomarker, Patient, Safety, Scientific misconduct, P.C, FDA, Loss, District court, Cassava, Journal, Defendant, Complaint, Alzheimer's disease, Neurobiology of Aging, Court, Cognition, Person, Pharmaceutical industry

Investors have until April 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Cassava is a clinical-stage biotechnology company.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.

Michael Austwick Joins Verona Pharma as Non-Executive Director

Retrieved on: 
Giovedì, Febbraio 1, 2024
Bachelor of Science, University, Head, Novartis, City University, VRNA, Information management, AstraZeneca, OrbiMed, Master of Science

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.

Key Points: 
  • LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.
  • Mr. Austwick has led the development and commercialization of more than 10 brands, covering inhaled and biologic assets at a country and global level.
  • “We are delighted to welcome Michael to the Board,” said Dr. David Ebsworth, Chairperson of Verona Pharma.
  • Dr. Ebsworth added: “We would like to thank Rishi for his numerous contributions to Verona Pharma’s successful development over the past 7 years.

Freedom Institute Welcomes Andrew Tatarsky, PhD, Pioneer and Founder of Integrative Harm Reduction Psychotherapy

Retrieved on: 
Giovedì, Gennaio 11, 2024
Hospitals, General Health, Health, Mental Health, Silver Hill Hospital, Patient, Addiction, City University, MD, SHARE, Multimedia, Partnership, Medical director, Tatarsky, City, Medicine, Doctor of Philosophy, LMHC, Substance abuse

View the full release here: https://www.businesswire.com/news/home/20240111045086/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240111045086/en/
    Andrew Tatarsky, PhD, Director of Clinical Programming at Freedom Institute (Photo: Business Wire)
    The founder of Integrative Harm Reduction Psychotherapy (IHRP) and a leader in the field, Dr. Tatarsky will build new IHRP-centered programming to treat the spectrum of substance use disorders and other addictive behaviors and will create and facilitate an internal IHRP training program.
  • Dr. Tatarsky will work in close collaboration with Freedom Institute Medical Director Ryan Wade, MD, and Director of Clinical Services Caroline Kern, LMHC, to integrate the harm reduction framework alongside the organization’s existing abstinence-based programs.
  • Tatarsky is a true groundbreaker,” said Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, which is currently working toward a partnership with Freedom Institute.
  • In addition to developing an internal IHRP training program, Dr. Tatarsky will also facilitate external educational programs through the Silver Hill Academy for Research and Education (SHARE) .

Neville Ray Appointed to Ziff Davis Board of Directors

Retrieved on: 
Mercoledì, Gennaio 10, 2024
Technology, Entertainment, Online, Communications, General Entertainment, Internet, Digital Marketing, Retail, Online Retail, Engineering, City University, Ziff Davis, T-Mobile US, T-Mobile, Security, ZD, CTIA (organization), Telecommunications, Mobile phone

Ziff Davis, Inc. (NASDAQ: ZD), today announced the appointment of Neville Ray to its Board of Directors, effective immediately.

Key Points: 
  • Ziff Davis, Inc. (NASDAQ: ZD), today announced the appointment of Neville Ray to its Board of Directors, effective immediately.
  • “We are delighted to welcome Neville to our Board of Directors,” said Ziff Davis Board Chair Sarah Fay.
  • “Neville’s extensive experience deploying wireless networks and overseeing technology operations at top companies in the telecom industry make him a valuable addition to our Board,” said Ziff Davis CEO Vivek Shah.
  • "I am thrilled to join the Board of Ziff Davis, and I look forward to working with Vivek and the full Ziff Davis team across its impressive roster of brands,” Ray said.

A UNIVERSAL CORONAVIRUS VACCINE COULD SAVE BILLIONS OF DOLLARS IF READY BEFORE NEXT PANDEMIC

Retrieved on: 
Giovedì, Gennaio 11, 2024
Death, Computation, National Science Foundation, Operations research, Infection, Research, City University, Tropical medicine, Manuscript, Agency, Health, BCM, Baylor College of Medicine, Absenteeism, Baylor University, PRI, CUNY, MERS, MBA, City, AHRQ, Public health, State, Graduate Center, CUNY, COVID-19, Health policy, Public health informatics, Doctor of Philosophy, Human services, Lancet, Messenger, Bangladesh Technical Education Board, SARS, SARS-CoV-2, Coronavirus, National school, Model

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- What if scientists had developed a universal coronavirus vaccine in the years prior to 2020 so that it was available at the start of the COVID-19 pandemic? A universal coronavirus vaccine targets parts of the virus that are common to either many or all coronaviruses, thereby offering some degree of protection against a range of strains. A new study suggests if such a vaccine were available at the start of the pandemic, it could have saved millions of lives, prevented suffering, and saved billions of dollars in direct medical and other costs until the strain-specific (i.e., SARS-CoV-2) vaccine went through the entire development, testing, and emergency use authorization process that lasted 10 months.

Key Points: 
  • NEW YORK, Jan. 11, 2024 /PRNewswire/ -- What if scientists had developed a universal coronavirus vaccine in the years prior to 2020 so that it was available at the start of the COVID-19 pandemic?
  • A universal coronavirus vaccine targets parts of the virus that are common to either many or all coronaviruses, thereby offering some degree of protection against a range of strains.
  • The experiments simulated what would happen if a universal coronavirus vaccine was available at the start of the COVID-19 pandemic.
  • A universal coronavirus vaccine was also shown to be highly cost-effective even if a more specific and more efficacious vaccine came to market.